Physician profile
Sara E Taylor
NPI 1164083143
$1,342.14
in general payments reported to CMS, 2019-2025
13 companies · $93.68 in 2025
The $93.68 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.24 · 2020: $66.27 · 2021: $220 · 2022: $318 · 2023: $174 · 2024: $403 · 2025: $93.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.29 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $369.24 | 2020-2022 | |
| Alcon Vision LLC | $218.45 | 2019-2025 | Hydrus Microstent, Precision 1, Rocklatan |
| Oyster Point Pharma, INC. | $209.83 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $186.98 | 2019-2024 | |
| Abbvie INC. | $63.71 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Coopervision INC. | $63.23 | 2024 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $51.42 | 2023-2024 | Cequa |
| Harrow Eye, LLC | $42.32 | 2023 | Iheezo |
| Johnson & Johnson Vision Care, INC. | $38.67 | 2019-2021 | |
| Thea Pharma INC. | $31.24 | 2023 | Iyuzeh |
| Dompe US, INC. | $25.90 | 2024 | Oxervate |
| Rxsight INC | $25.59 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $15.56 | 2023 | Vyzulta, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.